Celera (CRA) Presents Data Describing an Immunodiagnostic Assay to Detect Lung Cancer from Blood Serum
Tweet Send to a Friend
Celera Corporation (NASDAQ: CRA) announced the presentation of data describing a novel mass spectrometry-based approach to identify and validate circulating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


